Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NIjYeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rOU|AuOTBizszN NX;rNm17OC12IHS= NXf6VotrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoDpNlY4ODJ5OES=
HepG2 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojpNE0yOCEQvF2= MV2wMVQh\A>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWeyOlcxOjd6NB?=
HT29 MYfGeY5kfGmxbjDBd5NigQ>? M2\JTVUxyqCwTR?= NV;3dWU{OjRvN{KgbC=> NXvGe5c1cW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh M3vHZ|I3PzB{N{i0
HepG2 NHX3W|BHfW6ldHnvckBCe3OjeR?= MnTTOVDDqG6P MXuyOE04OiCq NGfD[llqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> MX6yOlcxOjd6NB?=
HCC827 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnmV2JUPS95LkWvNVAhdk1? M4\hRlczyqCq MkHUSG1UVw>? MWjlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NF3DT|gzPjZ5NUS4OC=>
A549  MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjiNVAwOTVxMkCgcm0> NVS2OW5GPzMEoHi= NELCOlRFVVOR NXTxbWw6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= Moi1NlY3PzV2OES=
NCI-H460  NXvzOFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\IN2FiOTBxMkCvN|Ahdk1? M3myV|czyqCq M4ruZ2ROW09? M2rGNIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NYPtT25yOjZ4N{W0PFQ>
J89GFP NHznUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1SG1UV8Li MX\FR|UxRTR7Lki1JOKyKDF{Lk[1JI5O NVXJ[lhxOjZ3NkO1Olg>
THP89GFP NGPCbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqxSG1UV8Li MXPFR|UxRTF7LkO0JOKyKDZwNEOgcm0> NYS5[YlMOjZ3NkO1Olg>
SK-NEP-1 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfNdpcxNjBz4pETNVAvOCEQvF2= Mkf2NlQhcA>? M1zKd2ROW00EoB?= NFjFcXdKSzVyPUe2MlM1KG6P NVjBb2ROOjZzN{[yNVk>
G401 NHvrWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DIdlAvODIkgKOxNE4xKM7:TR?= M3H6cFI1KGh? MnjsSG1UV8Li M{ntSWlEPTB;MUSzMlAzKG6P NWP1cGxOOjZzN{[yNVk>
SK-NEP-1 NUP4do4xS2WubDDWbYFjcWyrdImgRZN{[Xl? MUC1NEBvVQ>? MYKx5qCUPCCm NWHOPYg5TE2VT9Mg MYfy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NYPMN3NtOjZzN{[yNVk>
G401 M2HkWWNmdGxiVnnhZoltcXS7IFHzd4F6 Ml;jOVAhdk1? M{iwN|HjiJN2IHS= MVvEUXNQyqB? M2jSe5Jm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NFnTW2EzPjF5NkKxPS=>
SK-NEP-1 M2Pab2Fxd3C2b4Ppd{BCe3OjeR?= NHWzO|I2OC9zMECgcm0> MnHTNlQhcA>? MlTaSG1UV8Li NULJWGdkcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF7o[GUzPjF5NkKxPS=>
G401 Mn;DRZBweHSxc3nzJGF{e2G7 MnXrOVAwOTByIH7N NWO4Ump1OjRiaB?= MXnEUXNQyqB? M{CxNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVq4RWllOjZzN{[yNVk>
SK-NEP-1 MXXGeY5kfGmxbjDBd5NigQ>? M4XHTFUxNzFyMDDuUS=> MXmyOEBp NHX0V2JFVVORwrC= MUHzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v M1P0S|I3OTd4MkG5
G401 NHHVOHVHfW6ldHnvckBCe3OjeR?= NIK1UFY2OC9zMECgcm0> NF;EZlYzPCCq M4K2[mROW00EoB?= MWfzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v MWiyOlE4PjJzOR?=
SK-NEP-1 NHzUemJHfW6ldHnvckBCe3OjeR?= MoW4OVAwOTByIH7N M4\rV|I1KGh? NVPaVY56TE2VT9Mg NIDZXJNqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? NFTkOowzPjF5NkKxPS=>
G401 NXfwN5NETnWwY4Tpc44hSXO|YYm= NVnVWW1sPTBxMUCwJI5O MmTBNlQhcA>? NHzSSpJFVVORwrC= MoHtbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> M1jkXFI3OTd4MkG5
RPMI 8226 NITHNlVE\WyuIGP1dpZqfmGuIFHzd4F6 NISz[HUzNzRxNjDuUS=> NFzQRpI1QOLCiXi= NX\PfFlucW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NVvJO2xbOjZyMECyPVI>
OPM2 M{fmfWNmdGxiU4Xyeol3[WxiQYPzZZk> NFTZR5EzNzRxNjDuUS=> MXK0PQKBkWh? MnKzbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MV:yOlAxODJ7Mh?=
U266 NUXxSlBuS2WubDDTeZJ3cX[jbDDBd5NigQ>? MW[yM|QwPiCwTR?= MkLtOFjjiImq NXL6TIZQcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MWKyOlAxODJ7Mh?=
H929 NHvmR|hE\WyuIGP1dpZqfmGuIFHzd4F6 MV6yM|QwPiCwTR?= M4fyTlQ56oDLaB?= M37UN4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? M1;xclI3ODByMkmy
RPMI 8226  M3PXNmFxd3C2b4Ppd{BCe3OjeR?= NHXO[|M16oDLbl2= NI\TWY4zPC92ODDo NH\6XZVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NFLBbnkzPjByMEK5Ni=>
HCC827 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoezNVAhdk1? NIG1U3I1QCCq NVq3Z4NOTE2VTx?= M1rPT4VvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi MoPZNlU6PDR4MUe=
NCI-H23 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LOfFExKG6P M3r2Z|Q5KGh? NGWzUmlFVVOR M2XVWIVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi M13NVVI2QTR2NkG3
AML3 M3TWfWZ2dmO2aX;uJGF{e2G7 MVewMVEh|ryP MkPqNlTDqGh? M3\rOolv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmP1NlU3OTJ7NEG=
ML-1 NWfROpJmTnWwY4Tpc44hSXO|YYm= MX:wMVEh|ryP NYKzeIJrOjUEoHi= NHPyWmNqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX7QfYJjOjV4MUK5OFE>
RPMI-8226vr10  Ml3vSpVv[3Srb36gRZN{[Xl? NWHQVYpCOC1zIN88US=> NVW2NVVQOjUEoHi= M4m5TYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{DwblI2PjF{OUSx
ML-1 NH7uS4dHfW6ldHnvckBCe3OjeR?= MWmxJO69VQ>? M4DoclI1yqCq NYn3OHZtcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> MYCyOVYyOjl2MR?=
RPMI-8226vr10  MnKzSpVv[3Srb36gRZN{[Xl? MkXmNUDPxE1? MoraNlTDqGh? Ml;UbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> MmrBNlU3OTJ7NEG=
SK-N-BE (2) NHW4RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVeyOQKBkWh? MlzGTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MXyyOVMxQDlzNh?=
SK-N-BE (2), PAN  MK MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VcFI16oDLaB?= M4r6UWlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= NIjTNWMzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN NVTvUXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzyR5hsOjUkgJno MYDJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P MmnuNlU{ODh7MU[=
SK-N-AS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2foPFI16oDLaB?= NHSzd5RKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= MWSyOVMxQDlzNh?=
SK-N-DZ MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrZPWp6OjUkgJno MkDHTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? NYLqOmRGOjV|MEi5NVY>
Caki-1 M3fHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNE8zPS93MDDuUS=> M2\IT|Q5KGh? M3LPRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MYqyOVI4QTF7MR?=
ACHN MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNE8zPS93MDDuUS=> MVq0PEBp NYXpcG9XcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NFXHeFkzPTJ5OUG5NS=>
769-P NG[zN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIflcXgyOC9{NT:1NEBvVQ>? M3rZV|Q5KGh? M4LkRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NIXtNGgzPTJ5OUG5NS=>
786-O  MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNE8zPS93MDDuUS=> M3ThdlQ5KGh? NHnSZm9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MWCyOVI4QTF7MR?=
Caki-1 NFPqWpZCeG:ydH;zbZMhSXO|YYm= MXm1NEBvVQ>? NX7rSpdPPDhiaB?= NHfqdJBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NHHqUYMzPTJ5OUG5NS=>
ACHN MlTORZBweHSxc3nzJGF{e2G7 MV:1NEBvVQ>? MX:0PEBp M2XPOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NFvDb|IzPTJ5OUG5NS=>
769-P M3rldmFxd3C2b4Ppd{BCe3OjeR?= NXnXPZkyPTBibl2= NE\WOJY1QCCq NVrRWYJtcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NYDCZmxqOjV{N{mxPVE>
786-O  NGGzPHhCeG:ydH;zbZMhSXO|YYm= Mn7DOVAhdk1? MX:0PEBp NWjIZXRocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MlPkNlUzPzlzOUG=
Caki-1 NYqwTnJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSyOU82OCCwTR?= M4D3TVQ5KGh? M33IfmROW09? MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk NIT6bG4zPTF5NkO1OC=>
ACHN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvK[FIzPS93MDDuUS=> NHXXe3E1QCCq MlLrSG1UVw>? NYSzV|VwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MWSyOVE4PjN3NB?=
769-P M4jRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXiTZZlOjVxNUCgcm0> MV60PEBp NHWzUo5FVVOR Mo\QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NGXKN2YzPTF5NkO1OC=>
Caki-1 NVe0PYpjS2:ub375JGZwem2jdHnvckBCe3OjeR?= NF3RXWo2OCCwTR?= NG\nemE4NTF2IHS= Mn\JSG1UVw>? NXXrdoY2e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? NXrUZXdOOjVzN{[zOVQ>
ACHN Mn7hR49td267IF\vdo1ifGmxbjDBd5NigQ>? NX\EXHVpPTBibl2= MoSwO{0yPCCm NG\VeIdFVVOR MVzzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MnzXNlUyPzZ|NUS=
769-P MXLDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NGPsZ5c2OCCwTR?= M{PwN|cuOTRiZB?= MlvDSG1UVw>? NFTacph{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MV[yOVE4PjN3NB?=
Caki-1 M2HDbGFxd3C2b4Ppd{BCe3OjeR?= M4Ow[VUxKG6P NVezVZl{PDhiaB?= M2[zTmROW09? MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVWyOVE4PjN3NB?=
ACHN Mnq0RZBweHSxc3nzJGF{e2G7 MnfQOVAhdk1? NG\LbpU1QCCq MWrEUXNQ MmrEbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUSyOVE4PjN3NB?=
769-P M1LCeGFxd3C2b4Ppd{BCe3OjeR?= NXmwR5ExPTBibl2= NIHPT3g1QCCq NXHIO|Z{TE2VTx?= NVHZOZRqcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlfxNlUyPzZ|NUS=
MDA-MB-231 MlHjUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MY[xNOKhdk1? NULq[oRvO8LiZB?= NFnh[GlFVVOR MU\hcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M4TnWlI1QDFyNEm3
BT-549 MVXNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> Moi3NVDDqG6P NV3Rc2plO8LiZB?= M4jyfWROW09? NWT5PGcz[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NXfBN|ZZOjR6MUC0PVc>
MCF-7  M1faTG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NYHtVYRNOTEEoH7N MYKzxsBl MWHEUXNQ MYjhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MonpNlQ5OTB2OUe=
MCF-7 NXW4V3J[TnWwY4Tpc44hSXO|YYm= NHXIclE2NTVyIH7N MXeyOEBp NF7EUmNFVVOR NIDWbppz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT|rFuIGDSJIFv\CCIb4jBNeKh MnvSNlQ{PjZ2MEe=
CTS M324emFxd3C2b4Ppd{BCe3OjeR?= NXPlXFdtOOLCk{SwJI5OyqB? MVK0PEBp M1zj[4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYCyOFI1PDR{OR?=
OCI-AML3  MoXORZBweHSxc3nzJGF{e2G7 NXPNe444OOLCk{SwJI5OyqB? MoryOFghcA>? MmLnbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1vUfFI1OjR2NEK5
U937 NXvKT5ptSXCxcITvd4l{KEG|c3H5 NYi3ZXBtOOLCk{SwJI5OyqB? MVu0PEBp NY\JOIlKcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmXONlQzPDR2Mkm=
PC3 NFHkdFNCeG:ydH;zbZMhSXO|YYm= MnnBNE0yODBibl2= MlPwNlQwPDhiaB?= MmDCbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGjuOHMzPDF4M{KzNC=>
PC3-AR NWnwZ3FZSXCxcITvd4l{KEG|c3H5 M3Tze|AuOTByIH7N NWnB[o9JOjRxNEigbC=> NH3pboNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1zhOFI1OTZ|MkOw
PC3 NX7Nc5V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq2NE0yODBibl2= MX2yOE81QCCq NXPIfmV5cW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= Moi2NlQyPjN{M{C=
PC3-AR NUTlcHE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMVExOCCwTR?= NUXKUplNOjRxNEigbC=> NEjnVo5qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= NGLCSWYzPDF4M{KzNC=>
PC3 NH3DZ2FHfW6ldHnvckBCe3OjeR?= M2DaU|AuOTByIH7N NVrMVZVwOjRiaB?= MUDzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NYHtW402OjRzNkOyN|A>
PC3-AR M3G5RWZ2dmO2aX;uJGF{e2G7 M4judlAuOTByIH7N MmDINlQhcA>? Ml\Od5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MUmyOFE3OzJ|MB?=
OS-RC-2 NVfnV2tWS2WubDDWbYFjcWyrdImgRZN{[Xl? M4ThZ|AuOTByMDDuUS=> NWfmOYIxOjRxNEivO|IhcA>? M{[5SmROW09? M1XHXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MofQNlQyPDR5M{e=
OS-RC-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXDOVAhdk1? MYW0PEBp M{jNWGROW09? MnzNbY5lfWOnczDHNk9OKGG{cnXzeC=> MnvVNlQyPDR5M{e=
OS-RC-2 NGfXUHlCeG:ydH;zbZMhSXO|YYm= NW\EVppzPTBibl2= MlzYOFghcA>? MVvEUXNQ Mo\ZbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1nHV|I1OTR2N{O3
SK-N-AS NHrzRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNO4dIOOLCk{iwJI5O MXS0PEBp MlfJTWM2OD1{Nz60JI5O NXTSe2tqOjRyOUi3PVk>
SK-N-DZ MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XSZ|DjiJN6MDDuUS=> NX\uXHhCPDhiaB?= NITHUINKSzVyPUKxMlkhdk1? MUmyOFA6QDd7OR?=
SK-N-SH Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqw5qCUQDBibl2= MlTGOFghcA>? NY\Gd5RtUUN3ME23Nk4{KG6P NVXaOm9IOjRyOUi3PVk>
SK-N-BE M1zJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:zNQKBmzhyIH7N MX:0PEBp MXjJR|UxRTd3LkSgcm0> NHu2d3EzPDB7OEe5PS=>
SK-N-AS NWXRNHFbSXCxcITvd4l{KEG|c3H5 MkPuNQKBmzhyIH7N MmXxOFghcA>? MVLwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M1jqc|I1ODl6N{m5
SK-N-DZ M2\IUGFxd3C2b4Ppd{BCe3OjeR?= MoD2NQKBmzhyIH7N M13mTlQ5KGh? MkK5dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MX[yOFA6QDd7OR?=
SK-N-SH MVLBdI9xfG:|aYOgRZN{[Xl? M17KclDjiJN2MDDuUS=> Mn\NOFghcA>? NYX0O|hQeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NYPSe4lyOjRyOUi3PVk>
SK-N-BE NXTYNGYzSXCxcITvd4l{KEG|c3H5 Mk\QNQKBmzRyIH7N NV;K[pFwPDhiaB?= NFq5c5Fxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MmjyNlQxQTh5OUm=
SK-N-AS M{fJOWZ2dmO2aX;uJGF{e2G7 NEHufHUx6oDVOECgcm0> MVu0PEBp NEfUS4JqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NVz3cG5iOjRyOUi3PVk>
SK-N-DZ MVXGeY5kfGmxbjDBd5NigQ>? MW[w5qCUQDBibl2= M2DWWlQ5KGh? MWnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M{TqPFI1ODl6N{m5
SK-N-SH Mn\FSpVv[3Srb36gRZN{[Xl? NWD0SlNrOOLCk{SwJI5O M3jrO|Q5KGh? NVPKW25McW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MoLZNlQxQTh5OUm=
SK-N-BE NGnWSZhHfW6ldHnvckBCe3OjeR?= MlLLNQKBmzRyIH7N NH;aPVU1QCCq NVXMVWNPcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NFW2[5EzPDB7OEe5PS=>
HCC-LM3 NI\1[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTyV49mOS1zMECwJI5O MojSNlQwPDhxN{KgbC=> NVjSSYxGTE2VTx?= NFvpVVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3XhSlI1ODl|OUW2
HepG2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;jNU0yODByIH7N MkLKNlQwPDhxN{KgbC=> M3Lwe2ROW09? MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NELrT4wzPDB7M{m1Oi=>
SMMC-7721 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP2SosyNTFyMECgcm0> M4TLW|I1NzR6L{eyJIg> NXj4WVBSTE2VTx?= NX3U[Zg3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXWyfnFyOjRyOUO5OVY>
HCC-LM3 NH6wO|BCeG:ydH;zbZMhSXO|YYm= MX[1NEBvVQ>? NGnTNVE1QCCq NE\NdoFFVVOR M2C4bolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NVjLZoROOjRyOUO5OVY>
HepG2 NFW0ZmZCeG:ydH;zbZMhSXO|YYm= MX[1NEBvVQ>? MXe0PEBp NImyU4lFVVOR MlS2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MVeyOFA6Ozl3Nh?=
SMMC-7721 M4L4PWFxd3C2b4Ppd{BCe3OjeR?= NEHKVoQ2OCCwTR?= MXm0PEBp MWrEUXNQ M4TrVYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NETLdGszPDB7M{m1Oi=>
HCC-LM3 M1uwfGZ2dmO2aX;uJGF{e2G7 MmezOVAwOTByIH7N Mm\ONlQhcA>? MkL0SG1UVw>? MVXk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MYOyOFA6Ozl3Nh?=
HepG2 M1ewemZ2dmO2aX;uJGF{e2G7 MmfmOVAwOTByIH7N M1\B[lI1KGh? NVnTRVM4TE2VTx?= MmnQ[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NWXaOI5YOjRyOUO5OVY>
SMMC-7721 MXHGeY5kfGmxbjDBd5NigQ>? M{W2e|UxNzFyMDDuUS=> M17jUVI1KGh? MXvEUXNQ NYXkSm5M\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MoLNNlQxQTN7NU[=
HCC-LM3 M37LcGZ2dmO2aX;uJGF{e2G7 MWW1NE8yODBibl2= M2PpSFI1KGh? MmezSG1UVw>? Mlv4[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MVGyOFA6Ozl3Nh?=
HepG2 NVvz[mxrTnWwY4Tpc44hSXO|YYm= NIfydIQ2OC9zMECgcm0> MVyyOEBp NY\WcWR[TE2VTx?= NXPTVI9s\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MkPxNlQxQTN7NU[=
SMMC-7721 NHS5VYJHfW6ldHnvckBCe3OjeR?= NF34c202OC9zMECgcm0> NWXMWlFvOjRiaB?= M1XlNWROW09? NV7vSZg{\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= M2L4N|I1ODl|OUW2
FaDu NI\sRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrrNmIyODEkgJXuUS=> NUPveXE2QC9zMD:xNkBp NHHPNpRlcXOybHH5[YQh[SC|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W= MnjFNlQxOjZ2OEK=
FaDu NFPZNmdHfW6ldHnvckBCe3OjeR?= M2H1fFExOOLChX7N NYHkZYZ2Oi92L{ivNVIhcA>? M2KyO4lv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w M2DM[lI1ODJ4NEiy
PC-3  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMXIExNTFyIN88US=> MnKyNlQwPDhxN{KgbC=> NWXYNos{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUKyN|k6OTJzNh?=
LNCaP M4PzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknXNE02KM7:TR?= M3vhSVI1NzR6L{eyJIg> Mn61bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn;KNlM6QTF{MU[=
RWPE-1  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHtWZoxNTJyIN88US=> NXHSe5gyOjRxNEivO|IhcA>? NF[5VYVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYOyN|k6OTJzNh?=
Capan-1 Ml32SpVv[3Srb36gRZN{[Xl? NU\PT2ZKOjVxNUCvNVAxKG6P MV64M|I1NzR6IHi= M{mwR2ROW09? M2XjUoRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= MoLTNlM6OjJ6OE[=
L3.6pl NF7qbZJHfW6ldHnvckBCe3OjeR?= NX73RVZJOjVxNUCvNVAxKG6P NYPhUmFPQC9{ND:0PEBp MXfEUXNQ M1\YPYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NUTvTXp6OjN7MkK4PFY>
CFPAC-1  NGPHfIFHfW6ldHnvckBCe3OjeR?= MXWyOU82OC9zMECgcm0> MWi4M|I1NzR6IHi= NHX3SZRFVVOR NF\UZVBld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n M33HeFI{QTJ{OEi2
Capan-1 Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorlNlUwPTBxMUCwJI5O M4HvdVQ5KGh? NHHHZnlFVVOR NHXEUZJz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXiyN|kzOjh6Nh?=
L3.6pl MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ftV|I2NzVyL{GwNEBvVQ>? NXW2OHFjPDhiaB?= M1rlXWROW09? NVnPU4tZemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEfudmszOzl{Mki4Oi=>
CFPAC-1  M1vWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T5ZlI2NzVyL{GwNEBvVQ>? NIr0eHo1QCCq M1LvcWROW09? M{fu[pJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEf5U4ozOzl{Mki4Oi=>
Capan-1 NXP6SZp4SXCxcITvd4l{KEG|c3H5 M13TVlI2NzVyL{GwNEBvVQ>? Mln0OFghcA>? NFX1TXFFVVOR NInoSINqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1zOVVI{QTJ{OEi2
L3.6pl MmjPRZBweHSxc3nzJGF{e2G7 MXSyOU82OC9zMECgcm0> NXe0WndoPDhiaB?= MUDEUXNQ MVvpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYeyN|kzOjh6Nh?=
CFPAC-1  M{nTNGFxd3C2b4Ppd{BCe3OjeR?= M2HSeFI2NzVyL{GwNEBvVQ>? MYK0PEBp NHjOVIdFVVOR NHfCZpRqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MViyN|kzOjh6Nh?=
HN22 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMVIxKG6P M2n3UVI1NzR6IHi= M2XaSmROW09? MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MWGyN|g4PzJ|NR?=
HSC4  NUPnXWFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnSXYFmOC1{MDDuUS=> MkLyNlQwPDhiaB?= NXToe3pqTE2VTx?= M3\hNolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> M1rK[FI{QDd5MkO1
HN22 M13N[WFxd3C2b4Ppd{BCe3OjeR?= NHfQToIxNTJyIH7N NF\afoo1QCCq Mo\BSG1UVw>? MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mmi3NlM5Pzd{M{W=
HSC4  NHTP[pdCeG:ydH;zbZMhSXO|YYm= Mlr4NE0zOCCwTR?= NVGyb2JUPDhiaB?= MU\EUXNQ NEfnNVVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGn0PI8zOzh5N{KzOS=>
HN22 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETyVJYxNTJyIH7N M2OyTVQ5KGh? MWfEUXNQ NXThT2VYcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MnOyNlM5Pzd{M{W=
HSC4  MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMVIxKG6P M1LTVlQ5KGh? MojwSG1UVw>? MYXpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= MXWyN|g4PzJ|NR?=
HN22 M3fhcGZ2dmO2aX;uJGF{e2G7 M{jxV|AuOjBibl2= MYG0PEBp MYDEUXNQ NFLTVWF{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NXez[It2OjN6N{eyN|U>
HSC4  NIDQSmtHfW6ldHnvckBCe3OjeR?= M1rSXVAuOjBibl2= M3XQ[|Q5KGh? MkfiSG1UVw>? NWDUZ21ze3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh NGPCdJQzOzh5N{KzOS=>
Cal62 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofJTWM2OD1|MzFCtUA1KG6P NUHwOIZ4OjN6MkSwOlQ>
Hth7 M3XqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfRTWM2OD1zNTFCtUAzKG6P MVKyN|gzPDB4NB?=
Hth83 NGHIOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN2INMxJFUhdk1? NGLjeFQzOzh{NEC2OC=>
C643 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3rTWM2OD15MTFCtUAyOCCwTR?= MlLRNlM5OjRyNkS=
SW1736 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmxNlRwUUN3ME2zOUDDuSB6IH7N MVmyN|gzPDB4NB?=
T241 NFX4dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZ3INMxJFchdk1? M1ruRVI{QDJ2ME[0
T351 NH\5OoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j6c2lEPTB;NUCgxtEhOTBibl2= NXXUd5lKOjN6MkSwOlQ>
BHP2-7 NYfOSlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN5INMxJFYhdk1? MkHDNlM5OjRyNkS=
T238 NE\1NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXjTWM2OD1zLEWwNEDDuSB{MECgcm0> MmfFNlM5OjRyNkS=
HCT8 NVf2TGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LXeFczKGh? NV\1elc5TE2VTx?= Ml;5TWM2OD1zMj655qCKyrIkgJmxMlkhdk1? M2rXelI{Ojl7M{i4
H630 NVLafYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H3W|czKGh? M4q3ZWROW09? NH7RWoRKSzVyPUGyMlTjiIoEsfMAjVMvOSCwTR?= MmGyNlMzQTl|OEi=
cH630 5-FU-res NG[2UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV63NkBp MYnEUXNQ NIXxdGxKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= M1LTXVI{Ojl7M{i4
HCT116 M3TWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hsb|czKGh? MnPsSG1UVw>? MlTrTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? NVH5SY57OjN{OUmzPFg>
HCT116 p53−/− MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\JZ4c4OiCq M{X0b2ROW09? NUjtToZ1UUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= M2\L[FI{Ojl7M{i4
dHCT116 p21−/− NGPGRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzkTok4OiCq NGLXSGxFVVOR M2\iR2lEPTB;NT655qCKyrIkgJmxMlMhdk1? MnTVNlMzQTl|OEi=
HT29 M{exU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S4SFczKGh? MWHEUXNQ MnnXTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? NYHTSGdUOjN{OUmzPFg>
LoVo NIW4W5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjS5AxPzJiaB?= NIfRWplFVVOR NFnYenlKSzVyPUWuNgKBkcLz4pEJNE43KG6P NESyXo8zOzJ7OUO4PC=>
RKO M2juS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjmO|IhcA>? M4HvTWROW09? NY\QeYhpUUN3ME23MlnjiIoEsfMAjVIvOiCwTR?= NIL1fXQzOzJ7OUO4PC=>
SW480 NIrrbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG3NkBp MVjEUXNQ MYnJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? NEPxcoMzOzJ7OUO4PC=>
eSW620 NXjze4R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NkBp NF;VVpNFVVOR NYTnXWw5UUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= M2Syb|I{Ojl7M{i4

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID